These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 6714917

  • 41. [Usefulness of an electrophysiological study in the management of patients with tachyarrhythmias].
    Sugimoto T.
    J Cardiol; 1989 Mar; 19(1):317-21. PubMed ID: 2810048
    [Abstract] [Full Text] [Related]

  • 42. [Serial testing of antiarrhythmic agents using programmed stimulation in recurrent ventricular tachycardia].
    Lukl J, Cíhalík C, Heinc P.
    Vnitr Lek; 1992 Mar; 38(3):246-51. PubMed ID: 1595215
    [Abstract] [Full Text] [Related]

  • 43. [Value of experimental and clinical methods on the effectiveness and side effect profile of anti-arrhythmia agents].
    Kuck KH.
    Z Kardiol; 1992 Mar; 81 Suppl 4():151-5. PubMed ID: 1283932
    [Abstract] [Full Text] [Related]

  • 44. Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram.
    Steinbeck G, Bach P, Haberl R.
    J Am Coll Cardiol; 1986 Oct; 8(4):949-58. PubMed ID: 3760368
    [Abstract] [Full Text] [Related]

  • 45. [Evaluation of ventricular tachycardia by endocavitary stimulation. Apropos of 46 cases].
    Cassagneau B, Calazel J, Puel J, Fauvel JM, Bounhoure JP, Marin T, Narula OS.
    Arch Mal Coeur Vaiss; 1984 Jun; 77(6):652-60. PubMed ID: 6431929
    [Abstract] [Full Text] [Related]

  • 46. Discordance between ambulatory monitoring and programmed stimulation in assessing efficacy of class IA antiarrhythmic agents in patients with ventricular tachycardia.
    Kim SG, Seiden SW, Matos JA, Waspe LE, Fisher JD.
    J Am Coll Cardiol; 1985 Sep; 6(3):539-44. PubMed ID: 2411776
    [Abstract] [Full Text] [Related]

  • 47. [Long-term drug therapy of arrhythmias (with special reference to ventricular tachyarrhythmias].
    Gertsch M.
    Schweiz Med Wochenschr; 1984 Jan 21; 114(3):77-86. PubMed ID: 6199838
    [Abstract] [Full Text] [Related]

  • 48. [Therapy of ventricular arrhythmias].
    Frohner K.
    Wien Med Wochenschr; 1984 Oct 31; 134(19-20):448-57. PubMed ID: 6516421
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Electrophysiologic effects and clinical efficacy of mexiletine used alone or in combination with class IA agents for refractory recurrent ventricular tachycardias or ventricular fibrillation.
    Kim SG, Felder SD, Waspe LE, Fisher JD.
    Am J Cardiol; 1986 Sep 01; 58(6):485-90. PubMed ID: 3529910
    [Abstract] [Full Text] [Related]

  • 51. [Life-threatening ventricular arrhythmia during simultaneous administration of propafenone and sotatol].
    Gilewski W, Bednarska D, Sinkiewicz W.
    Kardiol Pol; 2009 Aug 01; 67(8):916-20; discussion 921. PubMed ID: 19784892
    [Abstract] [Full Text] [Related]

  • 52. Meobentine sulfate: antiarrhythmic and electrophysiologic effects assessed by programmed electrical stimulation and ambulatory monitoring in patients with complex ventricular tachyarrhythmia. Report of a multicenter evaluation.
    Anderson JL, Reid PR, Platia EV, Akhtar M, Ruskin JN, Schaal SF, Jueng P, Long RA, Wenger TL.
    Am Heart J; 1985 Oct 01; 110(4):774-84. PubMed ID: 3901715
    [Abstract] [Full Text] [Related]

  • 53. [Value of Holter's dynamic ECG a as predictor of the effectiveness of anti-arrhythmia therapy].
    Sanna GP.
    G Ital Cardiol; 1986 Aug 01; 16(8):663-6. PubMed ID: 3792732
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Electrophysiologic drug testing in patients with malignant ventricular arrhythmias: importance of stimulation at more than one ventricular site.
    Morady F, Hess D, Scheinman MM.
    Am J Cardiol; 1982 Nov 01; 50(5):1055-60. PubMed ID: 7137032
    [Abstract] [Full Text] [Related]

  • 56. [The diagnosis and possibilities for the anti-arrhythmia treatment of malignant ventricular disorders of the heart rhythm].
    Golitsyn SP, Malakhov VI, Bakalov SA, Sokolov SF, Krutanov IB, Levin ER, Mikhaĭlova GA, Chernousova TV.
    Ter Arkh; 1991 Nov 01; 63(9):38-44. PubMed ID: 1759219
    [Abstract] [Full Text] [Related]

  • 57. [Study of flecainide in the treatment of ventricular arrhythmia].
    Hug C, Koliopoulos N, Tardy C, Errera J, Puech P.
    Ann Cardiol Angeiol (Paris); 1983 May 01; 32(3):161-4. PubMed ID: 6193751
    [Abstract] [Full Text] [Related]

  • 58. [A new method for the evaluation of the success of anti-arrhythmic drug therapy and a paradoxical drug-induced arrhythmogenic effect in individual patients].
    Andresen D, von Leitner ER, Wegscheider K, Schröder R.
    Z Kardiol; 1984 Aug 01; 73(8):492-7. PubMed ID: 6208699
    [Abstract] [Full Text] [Related]

  • 59. The effect of caffeine on ventricular ectopic activity in patients with malignant ventricular arrhythmia.
    Graboys TB, Blatt CM, Lown B.
    Arch Intern Med; 1989 Mar 01; 149(3):637-9. PubMed ID: 2465748
    [Abstract] [Full Text] [Related]

  • 60. [Control of antiarrhythmic drug efficacy in patients with chronic recurrent ventricular tachycardia by electrical stimulation (author's transl)].
    Breithardt G, Seipel L, Haerten K, Abendroth RR, Loogen F.
    Z Kardiol; 1979 Nov 01; 68(11):725-30. PubMed ID: 543190
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.